Datroway is the first antibody-drug conjugate approved for EGFR-positive NSCLC, offering a new treatment class for patients with prior targeted therapy and chemotherapy. The drug targets tumor cells ...
Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results